eribulin liposome (HR19024) / Jiangsu Hengrui Pharma - LARVOL DELTA

A Study of HR19024 in Subjects With Advanced Solid Tumor (clinicaltrials.gov) - P1 | N=71 | Completed | Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting ➔ Completed | Phase classification: P1a ➔ P1 | N=180 ➔ 71 | Trial completion date: Jul 2023 ➔ Oct 2024 | Trial primary completion date: Jul 2023 ➔ Oct 2024

Enrollment change • Phase classification • Trial completion • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

A Study of HR19024 in Subjects With Advanced Solid Tumor (clinicaltrials.gov) - P1a | N=180 | Recruiting | Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

A Study of HR19024 in Subjects With Advanced Solid Tumor (clinicaltrials.gov) - P1a | N=180 | Not yet recruiting | Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

New P1 trial • Oncology • Solid Tumor